News & Updates

Show Multimedia Only

Mepolizumab cuts exacerbation, hospitalization and corticosteroids exposure in a young patient with severe Th2 asthma and marginal BEC level

14 Nov 2025 by

A 36-year-old Caucasian overweight female banker with increasingly severe allergic and asthma symptoms presented to our clinic in late October 2024, after consulting multiple doctors in the US and UK for many years. She had been a smoker since the age of 24 years and switched to vaping 18 months before presentation and was advised to stop smoking. Since a young age, she had frequently experienced shortness of breath on minimal exertion, sports-induced asthma and respiratory tract infections.

Mepolizumab cuts exacerbation, hospitalization and corticosteroids exposure in a young patient with severe Th2 asthma and marginal BEC level

14 Nov 2025

Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody

14 Nov 2025 by

Lung cancer remains the most common cancer and a leading cause of cancer-related mortality, with improved but still suboptimal survival outcomes despite advances in treatment. At a recent symposium chaired by Dr Shi-Feng Nyaw, Specialist in Clinical Oncology, Hong Kong, Professor Tianqing Chu, Consultant at the Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai, China, highlighted how tislelizumab, a novel immunotherapy agent, differs from other anti–programmed death receptor 1 (PD-1) therapies. She presented efficacy and safety data for tislelizumab in both squamous and non-squamous non-small-cell lung cancer (NSCLC) from RATIONALE-307/304 and her routine clinical practice. Additionally, Professor Victor Lee, Clinical Professor at the Department of Clinical Oncology, The University of Hong Kong, shared real-world cases illustrating the clinical benefits of tislelizumab in NSCLC patients.

Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody

14 Nov 2025

Expanding the paradigm of consolidation therapy in NSCLC and SCLC

23 Oct 2025 by

Concurrent chemoradiotherapy (cCRT) has long been the standard curative-intent treatment for stage III unresectable non-small-cell lung cancer (NSCLC) and limited-stage (LS) small-cell lung cancer (SCLC). Following cCRT, consolidation therapy with durvalumab, an anti–PD-L1 antibody, is considered the standard-of-care (SoC) for patients with stage III NSCLC with no actionable genomic alterations. However, uncertainty exists on consolidation therapy options with EGFR tyrosine kinase inhibitors (TKIs) for patients with EGFR-mutant NSCLC, given the established evidence supporting their use in both resectable and unresectable stages, as well as in LS-SCLC. At an industry-sponsored symposium, Professor Te-Chun Hsia of the China Medical University Hospital in Taichung, Taiwan, discussed evolving consolidation therapy strategies in lung cancer, highlighting the role of osimertinib, a third-generation EGFR TKI, in patients with unresectable stage III EGFR-mutated NSCLC, and durvalumab in those with LS-SCLC.

Expanding the paradigm of consolidation therapy in NSCLC and SCLC

23 Oct 2025

Unstable angina triggered by RSV infection in a patient with pre-existing CVD

26 Sep 2025 by

A 57-year-old male lorry driver, who was an ex-chronic smoker and had underlying chronic diseases, was hospitalized due to a 3-day history of fever, cough, and shortness of breath in April 2025.

Unstable angina triggered by RSV infection in a patient with pre-existing CVD

26 Sep 2025

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

16 Sep 2025

Stepping up to triple therapy with inhaled corticosteroid (ICS) plus a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA) is recommended for patients with chronic obstructive pulmonary disease (COPD) inadequately controlled with dual therapy. The use of single-inhaler therapy has also been recommended over the use of multiple inhalers, as convenience has been associated with better treatment adherence and effectiveness. This article highlights the results of the first real-world comparative effectiveness study of two single-inhaler triple therapy (SITT) formulations, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and budesonide/ glycopyrrolate/formoterol fumarate (BUD/GLY/FORM), in patients who stepped up from prior dual combination therapy.

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

16 Sep 2025

First experience with sotatercept for pulmonary arterial hypertension in Southern China

20 Aug 2025 by

A 77-year-old male chronic smoker with a history of diabetes mellitus, hypertension, coronary artery disease treated with stenting to left circumflex artery and ramus intermediate artery in 2015, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD) presented on 19 January 2024 with shortness of breath (SOB) on exertion, which began following an episode of COVID-19 in May 2023 and worsened after a subsequent COVID-19 episode in April 2024. Before the two COVID-19 episodes, the patient had good exercise tolerance and could manage a 1-hour hike.

First experience with sotatercept for pulmonary arterial hypertension in Southern China

20 Aug 2025

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

20 Aug 2025 by

A 65-year-old male with good past health presented in June 2024 with a 1-month history of cough.

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

20 Aug 2025

Advancing collaboration in COVID-19 care

16 Aug 2025

Held in June 2025 in Singapore, the Pfizer COVID-CONNECT Masterclass convened international experts to discuss the evolving challenges of COVID-19. Co-chaired by Dr Asok Kurup and Dr Luke Moore, this event assessed the ongoing global impact of the disease and explored evidence-based strategies across the patient journey from early identification to effective treatment.

Advancing collaboration in COVID-19 care

16 Aug 2025

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

At the recent COVID-CONNECT Masterclass, an expert-led session explored where COVID-19 stands among common viral infections today. In a non-promotional symposium supported by Pfizer, infectious disease specialist Dr Leong Hoe Nam, Mount Elizabeth Hospital Novena, Singapore, discussed strategies for managing viral infections and surge preparedness. Complementing this, Professor David Strain from the University of Exeter Medical School, UK highlighted the enduring burden of long COVID.

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

The growing range of treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) has made first-line decisions more complex and more critical. Patients are increasingly more aware of new and different treatment options and are seeking therapies that align with their personal values. As survival outcomes continue to improve, shared decision-making (SDM) plays a vital role in individualising care by integrating clinical evidence with what matters most to each individual. This article explores how SDM can support patient-centred care, drawing on insights from Professor James Yang and patient advocate Mark Brooke.

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

Mepolizumab cuts exacerbation, hospitalization and corticosteroids exposure in a young patient with severe Th2 asthma and marginal BEC level

Mepolizumab cuts exacerbation, hospitalization and corticosteroids exposure in a young patient with severe Th2 asthma and marginal BEC level

Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody

Real-world insights: Transforming NSCLC treatment with a modified anti–PD-1 antibody

Expanding the paradigm of consolidation therapy in NSCLC and SCLC

Expanding the paradigm of consolidation therapy in NSCLC and SCLC

Unstable angina triggered by RSV infection in a patient with pre-existing CVD

Unstable angina triggered by RSV infection in a patient with pre-existing CVD

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

First experience with sotatercept for pulmonary arterial hypertension in Southern China

First experience with sotatercept for pulmonary arterial hypertension in Southern China

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

Advancing collaboration in COVID-19 care

Advancing collaboration in COVID-19 care

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC